Last updated: 2026-09-07 06:50:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Collegium Pharmaceutical, Inc. (COLL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23.52, with a market capitalization of $753.28M and a P/E ratio of 15.33. Over the past 52 weeks, its price has ranged from $23.32 to $50.79. This page covers its latest market performance, valuation, price trends and company information.
$753.28M | |
$23.54 | |
$50.79 | |
$3.23 | |
$23.70 | |
700.02K | |
-- | |
15.33 | |
$50.79 | |
$23.32 | |
-- | |
-- |
Collegium Pharmaceutical, Inc. (COLL) last closed at $23.70 as of 2026-09-04 23:41:00, unchanged from the previous close of $23.70.
During the latest regular trading session, COLL traded between $3.23 and $50.79, with a volume of 700.02K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Collegium Pharmaceutical, Inc. (COLL) moved from $25.12 to $23.52, representing a decline of 6.37% ($1.60).
The stock traded between $23.32 and $24.29 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 959.93 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.7%
COLL is currently trading at $23.52, placing it 0.7% of the way from its 52-week low of $23.32 to its 52-week high of $50.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 423 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Collegium Pharmaceutical, Inc. (COLL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.